4D Pharma requests immediate suspension of its shares
24th Jun 2022 12:35
(Sharecast News) - Biotherapeutics developer 4D Pharma requested an immediate suspension of trading in its shares on Friday.
Read more4D Pharma reports progress in bladder cancer trial
27th May 2022 10:46
(Sharecast News) - Live biotherapeutics developer 4D Pharma announced progress in the phase 2 clinical trial in bladder cancer on Friday.
Read more4d Pharma gets FDA clearance for potential Parkinson's treatments
22nd Feb 2022 09:55
(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced on Tuesday that the United States Food and Drug Administration (FDA) has cleared investigational new drug applications for 'MRx0005' and 'MRx0029', for the treatment of Parkinson's disease.
Read moreMore positive data reported from 4D Pharma trial of 'Blautix'
24th May 2021 09:42
(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced additional positive data from its completed phase 2 trial of 'LBP Blautix' on Monday, in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D).
Read more4D Pharma taps John Beck as its new finance chief
1st Mar 2021 14:33
(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.
Read more4D Pharma taps John Beck as its new finance chief
1st Mar 2021 14:33
(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.
Read more4D Pharma inks collaboration with Merck and Pfizer
8th Feb 2021 16:25
(Sharecast News) - Biotherapeutics developer 4D Pharma announced a clinical trial collaboration and supply agreement with Merck and Pfizer on Monday, for 'Bavencio', or avelumab).
Read more4D Pharma makes progress with MRx0518 development programme
3rd Feb 2021 11:19
(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced progress on activities in its development programme for its lead immuno-oncology single strain 'live biotherapeutic' candidate MRx0518 on Wednesday.
Read moreNext part of tumour trial begins for 4D Pharma
6th Jul 2020 12:38
(Sharecast News) - Biotherapeutics developer 4D Pharma has begin the treatment of the first patients in part B of its phase 1 and 2 clinical trial of 'MRx0518' in combination with immune checkpoint inhibitor 'Keytruda', or pembrolizumab, it announced on Monday, in patients with acquired resistance to prior immune checkpoint therapy.
Read morePatient enrolment begins for 4D's Covid therapy candidate
2nd Jul 2020 12:14
(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced on Thursday that its phase 2 clinical trial of the oral immunomodulator 'MRx-4DP0004', for patients hospitalised with Covid-19, was now open to enrolment, with dosing of the first patients expected shortly.
Read more4D Pharma receives expedited approval for coronavirus study
20th Apr 2020 11:08
(Sharecast News) - Pharmaceutical company 4D Pharma received expedited acceptance from the UK Medicines and Healthcare Products Regulatory Agency on Monday to kick off a Phase II study of MRx-4DP0004 in patients with Covid-19.
Read more4D Pharma upbeat on key findings from Blautix study
17th Apr 2020 13:53
(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced key findings of a planned interim analysis in its 'BHT-II-0002' study in irritable bowel syndrome (IBS) on Friday.
Read more4D Pharma raising at least ?18m via placing and subscription
18th Feb 2020 09:26
(Sharecast News) - Live biotherapeutic pharmaceutical company 4D Pharma announced a proposed fundraising on Tuesday, by way of a placing and subscription of new ordinary shares and warrants, to raise gross proceeds of at least ?18m via an accelerated bookbuild process.
Read more4D Pharma inks research collaboration agreement with Merck & Co
8th Oct 2019 08:30
(Sharecast News) - 4D Pharma has entered into a research collaboration agreement with Merck & Co to discover and develop live biotherapeutics for vaccines.
Read more4D Pharma losses widen as it spends cash on development activities
21st May 2019 11:27
(Sharecast News) - Biotherapeutics development company 4D Pharma reported net assets of £45.8m in its final results on Tuesday, falling from £69.8m year-on-year.
Read more